Literature DB >> 15616383

ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction.

Piero Pollesello1, Alexandre Mebazaa.   

Abstract

PURPOSE OF REVIEW: The aim of this review is to highlight the most recent and interesting articles on the physiologic properties and functions of ATP-dependent potassium channels in the cardiovascular system and on the role of the potassium channel openers for the treatment of cardiovascular dysfunction. RECENT
FINDINGS: The initial efforts in the development of potassium channel openers focused on the management of systemic hypertension. Lately, the range of possible indications for potassium channel openers has increased to include pulmonary hypertension and stable angina pectoris. The discovery of a connection between the mitochondrial ATP-dependent potassium channels and the phenomenon of cardiac preconditioning created potential new uses for potassium channel openers in myocardial ischemia, inn unstable angina, in preoperative and perioperative settings, and for the preservation of organs for transplant.
SUMMARY: The most recent data on the physiologic roles of sarcolemmal and mitochondrial ATP-dependent potassium channels and the pharmacology of potassium channel openers in the cardiovascular system are summarized and discussed. Finally, the effects of potassium channel opener drugs including minoxidil, nicorandil, pinacidil, bimakalin, and levosimendan, a dual-action potassium channel opener and calcium sensitizer with inodilator and cardioprotective activity, are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15616383     DOI: 10.1097/01.ccx.0000145099.20822.19

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  8 in total

1.  Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial.

Authors:  Zaccaria Ricci; Cristiana Garisto; Isabella Favia; Vincenzo Vitale; Luca Di Chiara; Paola E Cogo
Journal:  Intensive Care Med       Date:  2012-04-18       Impact factor: 17.440

2.  Effects of chronic treatment with a low dose of nicorandil on the function of the rat aorta during ageing.

Authors:  Stéphanie Raveaud; Paulette Mezin; Nicole Lavanchy; Barry Starcher; Robert P Mecham; Jean Verdetti; Gilles Faury
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-03-26       Impact factor: 2.557

3.  2,2-Dimethyl-3,4-dihydro-2H-1,4-benzoxazines as isosteres of 2,2-dimethylchromans acting as inhibitors of insulin release and vascular smooth muscle relaxants.

Authors:  Bernard Pirotte; Xavier Florence; Eric Goffin; Philippe Lebrun
Journal:  Medchemcomm       Date:  2019-02-12       Impact factor: 3.597

4.  Successful use of levosimendan as a primary inotrope in pediatric cardiac surgery: An observational study in 110 patients.

Authors:  Reena Khantwal Joshi; Neeraj Aggarwal; Mridul Aggarwal; Rakesh Pandey; Veronique Dinand; Raja Joshi
Journal:  Ann Pediatr Cardiol       Date:  2016 Jan-Apr

Review 5.  Can We Prevent Mitochondrial Dysfunction and Diabetic Cardiomyopathy in Type 1 Diabetes Mellitus? Pathophysiology and Treatment Options.

Authors:  Aleksandra Cieluch; Aleksandra Uruska; Dorota Zozulinska-Ziolkiewicz
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

Review 6.  Levosimendan-induced venodilation is mediated by opening of potassium channels.

Authors:  Daniel Burkhoff; Stuart Rich; Piero Pollesello; Zoltán Papp
Journal:  ESC Heart Fail       Date:  2021-10-30

7.  Levosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury?

Authors:  Peter Onody; Rita Stangl; Andras Fulop; Oliver Rosero; David Garbaisz; Zsolt Turoczi; Gabor Lotz; Zoltan Rakonczay; Zsolt Balla; Viktor Hegedus; Laszlo Harsanyi; Attila Szijarto
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

8.  Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy.

Authors:  Elisa Passini; Ana Mincholé; Raffaele Coppini; Elisabetta Cerbai; Blanca Rodriguez; Stefano Severi; Alfonso Bueno-Orovio
Journal:  J Mol Cell Cardiol       Date:  2015-09-16       Impact factor: 5.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.